Ro 61-1790, a new hydrosoluble endothelin antagonist: General pharmacology and effects on experimental cerebral vasospasm

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 3, 1997, Pages 1110-1118

  Roux, Sébastien ^a,b   Breu, Volker ^a   Giller, Thomas ^a   Neidhart, Werner ^a   Ramuz, Henri ^a   Coassolo, Philippe ^a   Clozel, Jean Paul ^a   Clozel, Martine ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYL PYRIDINE 2 SULFONIC ACID 6 (2 HYDROXY ETHOXY) 5 (2 METHOXY PHENOXY) 2 (2 1H TETRAZOL 5 YL PYRIDIN 4 YL) PYRIMIDIN 4 YLAMIDE; CLAZOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; DRUG EFFECT; DRUG POTENCY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SUBARACHNOID HEMORRHAGE; VASOSPASM;

ANIMALS; CHO CELLS; CRICETINAE; DIOXANES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; PYRIDINES; PYRIMIDINES; RATS; RATS, INBRED WKY; RATS, WISTAR; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; SPODOPTERA; SUBARACHNOID HEMORRHAGE; SULFONAMIDES; TETRAZOLES;

EID: 0031456079     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. BATTISTINI, B. AND BOTTING, R.: Endothelins: A quantum leap forward. Drug News Perspect. 8: 365-391, 1995.
2. BERRIDGE, M. J., DAWSON, R. M. C., DOWNES, C. P., HESLOP, J. P. AND IRVINE, R. F.: Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides. Biochem. J. 212: 473-482, 1983.
3. BREU, V., BURRI, K., CASSAL, J. M., CLOZEL, M., HIRTH, G., LÖFFLER, B. M., MÜLLER, M., NEIDHART, W. AND RAMUZ, H.: Intern. Pat. Appl. WO 9619459. F. Hoffmann-La Roche. 1996.
4. BREU, V., HASHIDO, K., BROGER, C., MIYAMOTO, C., FURUICHI, Y., HAYES, A., KALINA, B., LÖFFLER, B. M., RAMUZ, B. AND CLOZEL, M.: Separable binding sites for the natural agonist endothelin-1 and the non-peptide antagonist bosentan on human endothelin-A receptors. Eur. J. Biochem. 231: 266-270, 1995.
5. BREU, V., LÖFFLER, B. M. AND CLOZEL, M.: In vitro characterization of Ro 46-2005, a novel synthetic non-peptide endothelin antagonist of ET(A) and ET(B) receptors. FEBS Lett. 334: 210-214, 1993.
6. BROCKWAY, B. P., MILLS, P. A. AND AZAR, S. H.: A new method for continuous chronic measurement and recording of blood pressure, heart rate and activity in the rat via radio-telemetry. Clin. Exp. Hyper. Theory Pract. A 13: 885-895, 1991.
7. 2+ mobilization. Cell Calcium 14: 663-671, 1993.
8. CLOZEL, M., BREU, V., GRAY, G. A., KALINA, B., LÖFFLER, B. M., BURRI, K., CASSAL, J. M., HIRTH, G., MÜLLER, M., NEIDHART, W. AND RAMUZ, H.: Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 270: 228-235, 1994.
9. DORSCH, N. AND KING, M.: A review of cerebral vasospasm in aneurysmal subarachnoid haemorrhage. J. Clin. Neurosci. 1: 19-26, 1994.
10. A receptor in the maintenance of deoxycorticosterone acetate-salt-induced hypertension. Br. J. Pharmacol. 114: 925-930, 1995.
11. KARAM, H., HEUDES, D., GONZALES, M. F., LÖFFLER, B. M., CLOZEL, M. AND CLOZEL, J. P.: Respective role of humoral factors and blood pressure in aortic remodeling of DOCA hypertensive rats. Am. J. Hypertens. 9: 991-998, 1996.
12. KASSELL, N., HELM, G., SIMMONS, N., PHILLIPS, C. AND CAIL, W.: Treatment of cerebral vasospasm with intra-arterial papaverine. J. Neurosurg. 77: 848-852, 1992.
13. A receptors and protein kinase C-dependent pathway in cerebral capillary endothelium. J. Neurochem. 65: 1588-1596, 1995.
14. KIOWSKI, W., SUTSCH, G., HUNZIKER, P., MULLER, P., KIM, J., OECHSLIN, E., SCHMITT, R., JONES, R. AND BERTEL, O.: Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 346: 732-736, 1995.
15. LÖFFLER, B. M. AND JACOT-GUILLARMOD, H.: A rabbit antiserum raised against the hexapeptide endothelin (16-21) shows different binding affinities for endothelin-1, -2 and -3. Life Sci. 50: 2001-2009, 1992.
16. MACDONALD, R., ZHANG, J., SIMA, B. AND JOHNS, L.: Papaverine-sensitive vasospasm and arterial contractility and compliance after subarachnoid hemorrhage in dogs. Neurosurgery 37: 962-967, 1995.
17. MIMA, T., YANAGISAWA, M., SHIGENO, T., SAITO, A., GOTO, K., TAKAKURA, K. AND MASAKI, T.: Endothelin acts in feline and canine cerebral arteries from the adventitial side. Stroke 20: 1553-1556, 1989.
18. A-selective receptor antagonist. J. Pharmacol. Exp. Ther. 276: 473-481, 1996.
19. PATEL, T. R., GALBRAITH, S., GRAHAM, D. I., HALLAK, H., DOHERTY, A. M. AND MCCULLOCH, J.: Endothelin receptor antagonist increases cerebral perfusion and reduces ischaemic damage in feline focal cerebral ischaemia. J. Cereb. Blood Flow Metab. 16: 950-958, 1996.
20. PATEL, T. R., GALBRAITH, S. L., MCAULEY, M. A., DOHERTY, A. M., GRAHAM, D. I. AND MCCULLOCH, J.: Therapeutic potential of endothelin receptor antagonists in experimental stroke. J. Cardiovasc. Pharmacol. 26: S412-S415, 1995.
21. PORCHET, F., CHIOLERO, R. AND DE TRIBOLET, N.: Hypotensive effect of nimodipine during treatment for aneurysmal subarachnoid haemorrhage. Acta Neurochir. (Wien) 137: 62-69, 1995.
22. ROUX, S., LÖFFLER, B. M., GRAY, G. A., SPRECHER, U., CLOZEL, M. AND CLOZEL, J. P.: The role of endothelin in experimental cerebral vasospasm. Neurosurgery 37: 78-85, 1995.
23. SHIGENO, T., CLOZEL, M., SAKAI, S., SAITO, A., GOTO, K., FINDLAY, J. M. AND DACEY, R. G. J.: The effect of bosentan, a new potent endothelin receptor antagonist, on the pathogenesis of cerebral vasospasm. Neurosurgery 37: 87-91, 1995.
24. STANIMIROVIC, D., YAMAMOTO, T., UEMATSU, S. AND SPATZ, M.: Endothelin-1 receptor binding and cellular signal transduction in cultured human brain endothelial cells. J. Neurochem. 62: 592-601, 1994.
25. UNGER, T., SCHÜLL, B., HUBNER, D., YUKIMURA, T., LANG, R. E., RASCHER, W. AND GANTEN D.: Plasma-converting enzyme activity does not reflect effectiveness of oral treatment with captopril. Eur. J. Pharmacol. 72: 255-259, 1981.
26. a-like endothelin receptor in brain capillary endothelial cells. Biochem. Biophys. Res. Commun. 220: 839-842, 1996.
27. YASUMA, Y., MCCARRON, R. M., STRASSER, A. AND SPATZ, M.: The role of ET receptors in postischemic cerebral hypoperfusion (Abstract). Stroke 28: 258, 1997.
28. A receptor expression in human cerebrovascular smooth muscle cells. Br. J. Pharmacol. 116: 2441-2446, 1995.
29. ZIMMERMANN, M., SEIFERT, V., LÖFFLER, B. M., STOLKE, D., STENZEL, W., YOUNG, W. AND SELMAN, W. R.: Prevention of cerebral vasospasm after experimental subarachnoid hemorrhage by Ro 47-0203, a newly developed orally active endothelin receptor antagonist. Neurosurgery 38: 115-120, 1996.
30. ZUCCARELLO, M., SOATTIN, G. B., LEWIS, A. I., BREU, V., HALLAK, H. AND RAPOPORT, R. M.: Prevention of subarachnoid hemorrhage-induced cerebral vasospasm by oral administration of endothelin receptor antagonists. J. Neurosurg. 84: 503-507, 1996.